ModiBlast Pharma

Modiblast Pharma is a preclinical-stage German biopharmaceutical company developing novel immunomodulatory cancer therapies. The company's proprietary approach focuses on the in vivo reprogramming of myeloid leukemic blasts into antigen-presenting dendritic cells of leukemic origin (DCleu) to stimulate both innate and adaptive anti-cancer immune responses. Its lead program, MB101, is a fixed-dose combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and prostaglandin E1 (PGE1) designed to promote hematological recovery and trigger leukemia-specific immune responses. Modiblast aims to provide an easy-to-use, self-administrable medicine to stabilize remissions and prevent relapses in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).